Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Mounjaro side effect explained as more than 220,000 Brits are expected to receive the drug over the next three years ...

A WOMAN who has lost 5.5 stone on Mounjaro in eight months has shared the advice everyone needs to hear. La Hauser, from the ...